Supplementary Table 2 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia

Supplementary Table 2 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia

<p>Supplementary Table 2</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Anna Eriksson (15352461) (author)
Kolejni autorzy:	Marie Engvall (9184887) (author), Lucy Mathot (15352464) (author), Albin Österroos (15352467) (author), Martin Rippin (15352470) (author), Lucia Cavelier (15352473) (author), Claes Ladenvall (15352476) (author), Panagiotis Baliakas (15352479) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Genetic biomarkers Prognostic biomarkers Hematological Cancers Leukemias Precision Medicine Translational Research
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Table1 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
od: Anna Eriksson (15352461)
Wydane: (2025)

Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
od: Bouchra Tawk (15389486)
Wydane: (2025)

Supplementary Figure 1. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 11 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 12 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 13 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 14 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 15 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 17 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 18 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 19 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 20 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 21 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 22. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 23. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 24 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 25 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 26 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 27 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 28 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 29 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 3 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 4. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 6 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 7 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 8 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 9 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Table 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Table 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Wydane: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
od: Anne-Florence Blandin (15056366)
Wydane: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
od: Athanasios Bikas (16006076)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_74letsncsnlrf8olvlm1h6u3bg